A Phase 1 interventional study of MK-5684 and Prednisone in Prostatic Neoplasms, sponsored by Merck Sharp & Dohme LLC. Completed at 1 site in United States. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-15.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies in Prostatic Neoplasms by Merck & Co., Inc — 4 open to participants now, 6 under way, 3 of them phase 3. Prostatic Neoplasms · Merck & Co., Inc.
Among the 22 studies in Prostatic Neoplasms by Merck & Co., Inc, this one is the 18th largest by enrollment, is one of 3 that started in 2024, is one of 6 in phase 1, and was the 19th registered.
7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →4 of the 22 studies in Prostatic Neoplasms by Merck & Co., Inc are open now, in 12 countries. Recruiting first, the newest first:
Merck Sharp & Dohme LLC · Sites in United States, Argentina, Australia and 32 more countries
Ages 18+ · Men only
Merck Sharp & Dohme LLC · Sites in United States, Argentina, Australia and 33 more countries
Ages 18+
Merck Sharp & Dohme LLC · Sites in United States, Australia, Brazil and 36 more countries
Ages 18+
Merck Sharp & Dohme LLC
Ages 18+ · Men only
By country, each count listing its studies:
Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years to 55 Years · male · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 7 · Phase 3 9
First in 2003; this study’s year is marked. 3 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 12 is below the median of 60 across 5,352 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 93 across the 22 interventional studies. Of the 15 that completed or were terminated, 6 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
1 of the studies in Prostatic Neoplasms by Merck & Co., Inc that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02861573Merck Sharp & Dohme LLCStudy of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365) | 2027-10-22 |
Add it to your calendar (.ics) → With an account.
Among the 22 studies in Prostatic Neoplasms by Merck & Co., Inc, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Researchers have designed a study medicine called MK-5684 as a new way to treat prostate cancer.
The purpose of this study is to learn what happens to MK-5684 in a person's body over time (a pharmacokinetic or PK study). Researchers will compare what happens to MK-5684 in the body when it is given with and without another medicine called diltiazem.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The main inclusion criteria include but are not limited to the following:
Exclusion Criteria:
The main exclusion criteria include but are not limited to the following:
History or presence of any of the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
On Day 1 a single dose of MK-5684 will be administered under fasting conditions and a single dose of HRT (prednisone and fludrocortisone) will be administered under fed conditions approximately 4.5 hours after MK-5684 dosing.
Drug: MK-5684 · Drug: Prednisone · Drug: Fludrocortisone acetate
There will be a washout of at least 5 days between MK-5684 dosing in Period 1 and the first diltiazem dosing in Period 2. In Period 2, diltiazem will be administered once daily (QD) for 6 consecutive days with a single dose of MK-5684 coadministered on Day 2 under fasting conditions. HRT (prednisone and fludrocortisone) will be administered under fed conditions QD on Days 2 through 5, approximately 4.5 hours after MK-5684 and/or diltiazem dosing.
Drug: MK-5684 · Drug: Prednisone · Drug: Fludrocortisone acetate · Drug: Diltiazem hydrocholoride
Administered via oral tablet per dosing regimen.
Administered at a dose of 2.5 mg or 5 mg dependent on HRT dosing regimen via oral tablets.
Administered at a dose of 0.05 mg per HRT dosing regimen via oral tablets.
Administered at a dose of 240 mg per dosing regimen via oral capsule (extended-release).
Area under the concentration versus time curve from 0 to infinity after single dosing (AUC0-inf) of MK-5684 in plasma
AUC0-inf of MK-5684 in plasma will be determined.
Time frame: Predose, and at designated timepoints up to 120 hours post-dose
Area under the concentration versus time curve from 0 to last quantifiable sample (AUC0-last) of MK-5684 in plasma
AUC0-last of MK-5684 in plasma will be determined.
Time frame: Predose, and at designated timepoints up to 120 hours post-dose
Area under the concentration versus time curve from 0 to Hour 24 (AUC0-24) of MK-5684 in plasma
AUC0-24 of MK-5684 in plasma will be determined.
Time frame: Predose, and at designated timepoints up to 24 hours post-dose
Maximum concentration (Cmax) of MK-5684 in plasma
Cmax of MK-5684 in plasma will be determined.
Time frame: Predose, and at designated timepoints up to 120 hours post-dose
Time to Maximum concentration (Tmax) of MK-5684 in plasma
Tmax of MK-5684 in plasma will be determined.
Time frame: Predose, and at designated timepoints up to 120 hours post-dose
Apparent terminal half-life (t1/2) of MK-5684 in plasma
t1/2 of MK-5684 in plasma will be determined.
Time frame: Predose, and at designated timepoints up to 120 hours post-dose
Apparent Clearance (CL/F) of MK-5684 in plasma
CL/F of MK-5684 in plasma will be determined.
Time frame: Predose, and at designated timepoints up to 120 hours post-dose
Apparent volume of distribution during terminal phase (Vz/F) of MK-5684 in plasma
Vz/F of MK-5684 in plasma will be determined.
Time frame: Predose, and at designated timepoints up to 120 hours post-dose
Number of participants who experience one or more adverse events (AEs)
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
Time frame: Up to approximately 39 days
Number of participants who discontinue study intervention due to an AE
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
Time frame: Up to approximately 39 days
Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
Ran from Jul 2024 to primary completion in Aug 2024, 0 months.
Of 212 industry-sponsored phase 1 interventional studies under Prostatic Neoplasms, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 62. This study's 0 months is below that.
Counting every sponsor, half of 456 studies reached it within 43 months; a quarter within 23 and three quarters within 68.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Opevesostat